

# Hycamtin (topotecan) capsules

| Override(s)         | Approval Duration |
|---------------------|-------------------|
| Prior Authorization | 1 year            |

| Medications                   | Quantity Limit |
|-------------------------------|----------------|
| Hycamtin (topotecan) capsules | N/A            |

## **APPROVAL CRITERIA**

Requests for Hycamtin (topotecan) capsules may be approved for the following indications, when accompanying criteria are met:

- I. Relapsed small cell lung cancer (SCLC).

**Note:** Hycamtin (topotecan) capsules have a black box warning regarding the potential for dose limiting toxicity of bone marrow suppression including neutropenia and thrombocytopenia. Because of this, Hycamtin should be administered only to individuals with adequate bone marrow reserves as defined as a baseline neutrophil count of greater than or equal to 1,500 cells/mm<sup>3</sup> and platelet count greater than or equal to 100,000 cells/mm<sup>3</sup>. Frequent monitoring of peripheral blood cell counts should be instituted during treatment.

| State Specific Mandates |     |     |
|-------------------------|-----|-----|
| N/A                     | N/A | N/A |

## **Key References:**

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2015. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed April 21, 2015.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2015; Updated periodically.